Century Therapeutics, Inc. (IPSC)

In Q1 2025, the company reported progress, including patient dosing in the Phase 1 CALiPSO-1 trial for CNTY-101 and the expansion of clinical trial sites to Europe. In Q2 2025, patient dosing continued in the CALiPSO-1 trial, with clinical data anticipated by year-end, and CNTY-308 entered IND-enabling studies. In Q3 2025, the company announced its lead iPSC-derived beta islet program for Type 1 diabetes (CNTY-813), with IND-enabling studies expected to begin by year-end and an IND submission targeted for 2026, and CNTY-308 was advancing through IND-enabling studies. On July 21, 2025, Century Therapeutics was upgraded to a Zacks Rank #1 (Strong Buy), but on November 17, 2025, Leerink downgraded it to Market Perform, citing the de-prioritization of CNTY-101. Insider selling activity was reported on September 8, 2025. On March 19, 2025, the company announced a pipeline re-prioritization, including the early discontinuation of the Phase 1 ELiPSE-1 trial. The company presented preclinical data at the AACR Annual Meeting 2024 and the ASGCT 28th Annual Meeting. Century Therapeutics participated in the Piper Sandler 37th Annual Healthcare Conference on November 25, 2025. The stock experienced a significant decline of 61.58% between November 18, 2024, and November 17, 2025.

Demand seasonality is not directly applicable to Century Therapeutics, as its products are in clinical development and not yet commercially available. However, the broader market for induced pluripotent stem cells (iPSCs) and stem cell-based therapies is experiencing increasing demand, driven by personalized medicine and the need for scalable stem cell production. The demand for advanced production and differentiation platforms for iPSC-derived models is sustained by the need for safer and more effective therapeutics.

Century Therapeutics, Inc. (IPSC) is a clinical-stage biotechnology company focused on developing transformative allogeneic cell therapies for autoimmune diseases and cancer, leveraging an induced pluripotent stem cell (iPSC) platform to create "off-the-shelf" cell therapies. The company engineers iPSCs to generate immune effector cells, primarily natural killer (NK) and T cells, for therapeutic use. Major product candidates include CNTY-101, an iPSC-derived CAR-iNK cell therapy targeting CD19; CNTY-308, a CD19-targeted CAR-iT cell therapy; CNTY-813, an iPSC-derived beta islet cell program for Type 1 diabetes; CNTY-341, an αβ iT cell program targeting CD19 + CD22; and a solid tumor program utilizing iT cells targeting Nectin-4. The company's Allo-Evasion™ technology is integrated into its product candidates to help avoid host rejection and potentially enhance the durability of clinical responses.

Century Therapeutics is headquartered in Philadelphia, Pennsylvania, with expanded operational and laboratory space there and a manufacturing facility in Branchburg, New Jersey. The company also has a presence in Boston, Massachusetts, a laboratory in Hamilton, Ontario, focused on glioblastoma, and a Seattle-based innovation hub.

Century Therapeutics' reputation has been shaped by its scientific advancements, clinical trial progress, and financial performance. Positive developments, such as the initiation of patient dosing in clinical trials and promising preclinical data presentations, contribute positively to its standing. An upgrade to a Zacks Rank #1 (Strong Buy) in July 2025 reflects a positive outlook, while analyst downgrades, such as the one from Leerink in November 2025, can impact investor perception. The overall stock price decline reflects challenges in market sentiment.

Century Therapeutics, Inc. has a diverse ownership structure, including institutional, public company, and individual investors. Major institutional owners include Bain Capital Life Sciences Investors, LLC, Renaissance Technologies Llc, Vanguard Group Inc, DAFNA Capital Management LLC, Casdin Capital, LLC, Syncona Portfolio Ltd, Two Sigma Investments, Lp, Tang Capital Management Llc, Venrock Healthcare Capital Partners III, L.P., Jane Street Group LLC, Raymond James Financial Inc., Prudential Financial Inc., Goldman Sachs Group Inc., Charles Schwab Investment Management Inc., JPMorgan Chase & Co., Sei Investments Co., Federated Hermes Inc., Cornercap Investment Counsel Inc., and Mirae Asset Global Investments Co. Ltd. Significant public company ownership includes Bayer Aktiengesellschaft, Versant Venture Capital VI LP, and Fujifilm Cellular Dynamics Inc. Insiders also hold shares in the company, with Brent Pfeiffenberger owning the most.